287 filings
8-K
FGEN
FibroGen Inc
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:12pm
10-Q
2024 Q1
FGEN
FibroGen Inc
Quarterly report
6 May 24
4:10pm
8-K
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
ARS
2023 FY
FGEN
FibroGen Inc
24 Apr 24
Annual report to shareholders
9:55pm
DEFA14A
FGEN
FibroGen Inc
24 Apr 24
Additional proxy soliciting materials
5:08pm
8-K
vfjphd gu1iwne0l9y
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
gaoul mo06i8gqc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
17k54gmcl mr
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
y4antk5l
5 Oct 23
Departure of Directors or Certain Officers
7:41pm
8-K
hm52vsudi sfulct6p
6 Sep 23
Departure of Directors or Certain Officers
8:55am
8-K
x6eo4z3 u4bj1fzb3
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
S-8
9svmm36jghhwy
7 Aug 23
Registration of securities for employees
4:22pm
8-K
c7xfl
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
0m4w55p
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
v94v6br
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
217 91um1
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am